Introduction
============

Non-small cell lung carcinoma (NSCLC) is one of the most diagnosed cancers in China [@B1]. Approximately 70%-80% of NSCLC patients are not eligible for radical surgery at the time of diagnosis, due to late diagnoses at stages III or IV. Although combination chemotherapy treatments with 2-3 drugs and radiotherapy are the main methods of treating locally advanced NSCLC, no standard regimen has been established at present [@B2],[@B3]. Because of the low response rates and the toxic side effects of chemotherapy and chemo-radiotherapy, outcomes for patients with advanced NSCLC remain poor [@B4],[@B5].

Paclitaxel-based chemotherapy is widely used as the first-line treatment for many cancers, including NSCLC. It has produced significant and incremental survival benefits [@B6],[@B7]. However, only 20%-40% of patients have shown sensitivity to this treatment [@B8]. Most of the patients had either primary resistance to the drug or acquired resistance after repeated treatments. Therefore, identification of the relevant response predictors will highly benefit clinical practice by stratifying patients into suitable treatment options that are currently available [@B9]. Although several molecules, including TUBB3, MDR1, and P16 proteins, are related to paclitaxel resistance [@B10]-[@B12], a clinical predictor for paclitaxel-based treatment is not yet available.

The *P16* gene is a cell cycle regulator involved in the inhibition of G1 phase progression. Methylation of the CpG islands near the transcription start site of the *P16* gene not only silences *P16* transcription but also represses transcription of the lncRNA *ANRIL* [@B13]-[@B15]. Aberrant *P16* methylation occurs frequently in NSCLC and gastric cancer and is associated with their development and progression [@B16]-[@B19]. Although it has been reported that *P16* methylation is correlated with treatment responses to fluorouracil-based therapy in breast tumors, colorectal cancer, and gastric cancer [@B20]-[@B22], the feasibility of using *P16* methylation to predict paclitaxel resistance has not previously been reported.

To determine if the *P16* methylation is related to paclitaxel chemosensitivity in the advanced NSCLC, in the present study, we analyzed the association between *P16* methylation and paclitaxel resistance in patients with NSCLC who were enrolled in a randomized phase III clinical trial [@B23]. The direct effects of *P16* methylation on the sensitivity of cancer cells to paclitaxel were also studied. The results indicate, for the first time, that *P16* methylation may directly decrease the paclitaxel sensitivity of cancer cells and might be used as a biomarker for predicting paclitaxel resistance of NSCLC.

Materials and Methods
=====================

Patients and sample collection
------------------------------

A multicenter phase III randomized 2-arm study was conducted to assess the effects of low-dose paclitaxel therapy (45 mg/m^2^ per week for 6 weeks) combined with 60-71 Gy radiotherapy for 134 patients with locally advanced NSCLC at clinical stage III from March 2006 to February 2013 at Peking University Cancer Hospital and Institute and reported according to the CONSORT guidelines [@B23]. Biopsy tissues of NSCLC were collected prior to chemotherapy and used for histological and cytological diagnoses. Among the 134 NSCLC patients who were enrolled in the clinical trial, 119 were from Peking University Cancer Hospital. Formalin fixed paraffin embedded (FFPE) NSCLC biopsies from 52 patients were available for *P16* methylation detection.

The primary endpoint of the study was the response rate, which was assessed by the RECIST criteria [@B24]. The responses were categorized as complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD). Patients with CR and PR were defined as responders, whereas patients with SD and PD were defined as non-responders. The secondary endpoints were recurrence-free survival and overall survival (RFS and OS).

These studies were approved by the Institutional Review Boards (IRB) at the Peking University Cancer Hospital and Institute (RCOG-0701), and all patients gave written informed consent to participate in the study. The study was performed in accordance with the ethical standards of the Declaration of Helsinki. The clinical trial was registered with the Chinese Clinical Trial Registry (ChiCTR-TRC-10000786).

Cell lines and culture
----------------------

*P16*-methylated lung cancer cell line H1299, was kindly provided by Dr. Chengchao Shou at Peking University Cancer Hospital and Institute. *P16*-unmethylated lung cancer cell line HCC827 was purchased from the National Infrastructure of Cell Line Resource (Beijing). *P16*-unmethylated gastric cancer cell line BGC823 was kindly provided by Dr. Yang Ke at the same Institute. The cells were cultured in RPMI1640 medium supplemented with 10% FBS and maintained at 37 °C in humidified air with 5% CO~2~.

DNA extraction and bisulfite modification
-----------------------------------------

Genomic DNA was extracted from the biopsies, and subjected to bisulfite treatment using the EpiTect Plus FFPE Bisulfite Kit (cat. no. 59144, Qiagen) according to the manufacturer\'s instructions. The modified DNA was stored at -20 °C before use.

Detection of *P16* methylation using the MethyLight assay, DHPLC, MSP, and sequencing
-------------------------------------------------------------------------------------

The primer and probe sequences used in the 70 bp MethyLight assay have been described previously (Fig. [1](#F1){ref-type="fig"}A) [@B25]. The *P16* methylation levels were determined using an Applied Biosystems 7500 Real-Time PCR System (Applied Biosystems, Foster City, CA, USA) and normalized to the internal control *COL2A1* gene (collagen type II, alpha 1 gene). The relative copy number (RCN) of the methylated-*P16* CpG islands was calculated according to the formula \[2^-ΔCt^, (ΔCt=Ct~methylated-p16~ - Ct~COL2A1~)\]. When the Ct value for *COL2A1* was ≤29.3, the tested sample was defined as *P16* methylation informative \[26\]. The methylation status of the *P16* CpG islands in cancer cells was detected with denatured high performance liquid chromatography (DHPLC) as described [@B19],[@B27]. Methylation-specific PCR (MSP; 150/151-bp) was also used to detect methylated-*P16* and unmethylated-*P16* alleles as described [@B28].

The 150 bp fragment of the *P16* exon-1 CpG island, containing with the entire 70 bp MethyLight amplicon, was amplified from bisulfite-templates using the CpG-free primer set (forward, 5\'-ggggagtagtatggagttt-3\'; reverse, 5\'-aaccctctacccacctaaa-3\') at annealing temperature 55 ºC for 40 cycles, and clone-sequenced (Fig. [1](#F1){ref-type="fig"}A).

Construction of vectors and transfection
----------------------------------------

To induce demethylation of *P16* CpG islands, an engineered P16-specific dioxygenase (P16-TET) pTRIPZ vector [@B29] was constructed by fusing a SP1-like engineered seven-zinc finger protein (7ZFP) capable of specifically binding the 21 bp fragment (5\'-GAG GAA GGA AAC [GGG GCG GGG]{.ul}-3\', including a [Sp1-binding site]{.ul}) within the human *P16* promoter with the catalytic domain (CD: 1418aa-2136aa) of TET1 (NM_030625.2), and then inserted into the expression controllable pTRIPZ vector carrying a Tet-on\' switch (Open Biosystem, USA) to control the expression of the P16-TET. The P16-TET stably transfected H1299 cells were treated with the doxycycline (final conc. 0.25 µg/ml) for 7 days for induction of demethylation of the *P16* CpG islands. Similarly, the engineered *P16*-specific methyltransferase (P16-Dnmt) was constructed by fused the 7ZFP with the catalytic domain (approximately 608-908aa) of mouse Dnmt3a, and integrated into the pcDNA3.1 vector (for transient transfection) and the pTRIPZ vector (for stable transfection) to induce methylation of the *P16* CpG islands as previously described [@B14]. The BGC823 cells stably transfected with P16-Dnmt or pTRIPZ empty control vectors were induced with 0.25 µg/ml doxcycline for 14 days, and then paclitaxel sensitivity was assessed using the cell viability assay, as shown below.

Extraction of RNA and quantitative RT-PCR (qRT-PCR)
---------------------------------------------------

Cells with the density about 70% were harvested. Total RNA was extracted by TRIzol (Invitrogen). The cDNA was reverse-transcribed using the ImProm-IITM Reverse Transcription System (A3800;Promega). The expression level of the *P16* gene was analyzed by quantitative RT-PCR as previously described [@B14]. Power SYBR Green PCR Master Mix (Fermentas, Canada) was used in qRT-PCR analyses (ABI-7500FAST). The average copy numbers of *P16* mRNA per cell was calculated based on the average Ct value of target gene and *Alu* reference \[2^-(Ct^~target_gene~^-Ct^~Alu~^)^\] [@B30].

Western blot
------------

Protein levels were detected using Western blot as previously reported [@B14]. The following antibodies were used: P16 (Proteintech), GAPDH (OriGene), MYC (Sigma).

Cell viability assay
--------------------

Cell proliferation was analyzed using the Cell Counting Kit-8 (CCK-8). Briefly, the stably transfected cells were seeded into 96-well plates at 1,000 cells per well, with three wells for each treatment. Following the adhesion of cells to the wells, the cells were treated with paclitaxel (30 mg/5 ml, Haikou Pharmaceutical Factory Co., Ltd) at various concentrations (final concentration, 0.03, 0.3, 3.0, and 30.0 µg/ml for H1299 and BGC823 cells; 0.03, 0.3, 3.0, and 30.0 ng/ml for HCC827 cells). The control reagent was 0.9% NaCl. The viable cell numbers were assessed 48 h after treatment. The half maximal inhibitory concentration (IC50) was calculated using the SPSS16.0 software.

Statistical analysis
--------------------

All statistical analysis was conducted with SPSS 16.0 software. The associations between gene methylation status and clinicopathologic characteristics and clinical response were assessed using Pearson\'s chi-square test unless the smallest expected value is \<5; then, Fisher\'s exact test was used. The forward binary logistic regression analysis was used to perform multivariate analyses. The Kaplan-Meier survival curve and log-rank test were used to describe RFS or OS. All *P*-values were two-sided, and *P* \< 0.05 was considered statistically significant.

Results
=======

Characteristics of the eligible NSCLC patients from the clinical trial
----------------------------------------------------------------------

Among the 52 available NSCLC biopsies, 45 were *P16* methylation informative (*COL2A1* Ct value ≤29.3) as assessed by the MethyLight analysis, and were therefore eligible for the association analysis. Among the 45 patients who received low-dose paclitaxel-based therapy, 18 patients were complete or partial responders (40.0%) and 36 patients (80.0%) died during the follow-up (range 7.4 to 77.4 months; *median*, 32.0 months). The median RFS and OS values for these patients were 9.9 and 21.0 months, respectively. The clinicopathological characteristics of these 45 patients are listed in Table [1](#T1){ref-type="table"}.

A receiver operating characteristic (ROC) curve for *P16* methylation was made based on the specificities and the sensitivities of response to determine the appropriate cutoff value (\>2.07×10^-4^) to define *P16* methylation-positive. The area under the curve is 0.652 (95% CI: 0.49-0.82, *P*=0.086, Fig. [2](#F2){ref-type="fig"}). Consequently, 15 NSCLC patients were *P16* methylation-positive, and 30 NSCLC patients were *P16* methylation-negative. The results of bisulfite-sequencing confirmed the MethyLight analysis: densely methylated CpG sites were observed in some *P16* alleles in two representative *P16* methylation-positive samples \#1 and \#2, and not observed in the *P16* methylation-negative sample \#3 (Fig. [1](#F1){ref-type="fig"}B). A C-deletion in*P16* exon-1 coding region was also identified. The *P16* methylation-positive rate in lung squamous carcinomas was significantly higher than that in lung adenocarcinomas or in large cell carcinomas (46.2% vs. 17.6% or 0.0%, *P*=0.031). Higher *P16* methylation-positive rate was observed in NSCLC patients who were \>60 years old than in those from patients \<60 years old (52.6% vs. 19.2%, *P*=0.019) (Table [1](#T1){ref-type="table"}).

*P16* methylation was associated with NSCLC resistance to low-dose paclitaxel
-----------------------------------------------------------------------------

Further analysis showed that *P16* methylation was significantly associated with a poor response to low-dose (45 mg/m^2^ per week for 6 weeks) paclitaxel-based treatment (Table [1](#T1){ref-type="table"}). The total response rate of the *P16* methylation-positive patients was significantly lower than that of the *P16* methylation-negative patients: 13.3% (2/15) vs. 53.3% (16/30) (*P*=0.004) (Table [1](#T1){ref-type="table"}). After adjusting for age, sex, pathology, and clinical stage, the differences in the response rates between the *P16* methylation-positive and *P16* methylation-negative patients were significant according to multivariate analyses (adjusted odds ratio= 0.085, 95% confidence interval \[CI\]: 0.012-0.579, *P*= 0.013; Table [2](#T2){ref-type="table"}). Furthermore, the Kaplan-Meier analysis showed that the OS of the *P16* methylation- positive patients was shorter than that of the *P16* methylation-negative patients, but the difference was not statistically significant (Fig. [S1](#SM0){ref-type="supplementary-material"}A). No significant differences in RFS values were observed (Fig. [S1](#SM0){ref-type="supplementary-material"}B). These results indicate that *P16* methylation is a potential biomarker for predicting resistance to paclitaxel-based therapy for NSCLC patients.

*P16* demethylation sensitized NSCLC cancer cells to paclitaxel treatment
-------------------------------------------------------------------------

To study whether *P16* demethylation sensitize cells to paclitaxel, an expression controllable P16-TET pTRIPZ vector was used to stably transfected H1299 cells, a *P16* homogenously methylated lung cancer cell line. *P16* demethylation and expression were detected in the P16-TET H1299 cells treated with doxycycline (Dox) for 7 days, but not detected in negative control (Fig. [3](#F3){ref-type="fig"}A and [3](#F3){ref-type="fig"}B). The paclitaxel IC50 values of these P16-TET H1299 cells were significantly lower than that of vector control cells (1.13 *vs* 2.15 µg/ml,*P*\<0.001; Fig. [3](#F3){ref-type="fig"}C).

*P16* methylation causes paclitaxel resistance in cancer cells
--------------------------------------------------------------

To further validate the causality between *P16* methylation and paclitaxel resistance, we induced *P16* methylation in another lung cancer cell line HCC827 through transient transfection with the P16-Dnmt vector and the pcDNA3.1 empty control vector. Methylated-*P16* alleles were detected by MSP in the HCC827 cells 48 hours after P16-Dnmt transfection (Fig. [4](#F4){ref-type="fig"}A). Decrease of P16 protein level was induced by *P16* methylation in these cells (Fig. [4](#F4){ref-type="fig"}B). As expected, the paclitaxel IC50 value of the P16-Dnmt cells increased from 18.2 to 24.0 ng/ml (*P*=0.049; Fig. [4](#F4){ref-type="fig"}C).

As described in the Discussion section, through re-analyzing our recently published data [@B22], *P16* methylation was also significantly associated to paclitaxel response of patients with gastric cancer. To investigate whether *P16* methylation directly leads to paclitaxel resistance in gastric cancer cells, we stably transfected BGC823 cells with the *P16-*specific methyltransferase P16-Dnmt as previously described [@B14]. An obvious peak for methylated P16 alleles was detected on the 14th doxycycline-treatment days in DHPLC analysis (Fig. [5](#F5){ref-type="fig"}A). Significant downregulation of P16 expression was also detected (Fig. [5](#F5){ref-type="fig"}B and C). The results of the cell viability analysis showed that the *P16*-methylated BGC823 cells were more resistant to paclitaxel toxicity than were the control cells. The paclitaxel IC50 value of the P16-Dnmt cells significantly increased from 0.18 to 0.81 µg/ml (*P*\<0.001; Fig. [5](#F5){ref-type="fig"}D).

Discussion
==========

Paclitaxel-based chemotherapy regimens have been widely used to treat NSCLC [@B6],[@B7]. However, because of drug resistance, only 20%-40% patients have been responsive to the regimens [@B8]. Although multiple studies have attempted to find biomarkers that could be used to predict which patients may benefit from this regimen, no feasible biomarker is available in clinical practice yet. In the present study, we observed that NSCLC patients who were *P16* methylation-positive had consistently and significantly lower paclitaxel response rates than *P16* methylation-negative patients. Our results showed that *P16-*specific methylation directly increased paclitaxel resistance in cancer cells. To our knowledge, this is the first study showing that *P16* methylation could be used to predict paclitaxel resistance in NSCLC patients.

As a CDK4 inhibitor, the P16 protein is a cell cycle regulator involved in the inhibition of G1 phase progression through the CDK4-CCND1-Rb pathway [@B31]. The activities of cell cycle regulation genes such as *P53*, *P16* and *P14*, which arrest the cell cycle and/or apoptosis, are closely associated with chemosensitivity to cancer treatments [@B32],[@B33]. Inhibition of CDK4 by CINK4 or palbociclib could enhance paclitaxel sensitivity in lung adenocarcinoma and ovarian cancer cells [@B34],[@B35]. Therefore, increased activity of CDK4 by *P16* methylation is supposed to reduce paclitaxel sensitivity. In consistent with this hypothesis, we found that *P16* methylation by P16-Dnmt directly increased the paclitaxel IC50 value of BGC823 cells, whereas reactivation of *P16* demethylation by P16-TET directly decreased the IC50 in H1299 cells. These results suggest that epigenetic inactivation of the *P16* gene may cause paclitaxel resistance and reactivation of this gene may sensitize cancer cells to paclitaxel treatment.

The long non-coding RNA (lncRNA) *ANRIL* is transcribed from the antisense-strand of *P15/P14/P16* gene. It was reported that enforced *ANRIL* overexpression increased paclitaxel resistance of A549 cells, a *P15/P14/P16* gene homogenously deleted NSCLC cell line [@B36]. We recently found *P16* methylation (or demethylation) not only inactivated (or reactivated) the transcription of the *P16* gene, but also repressed (or enhanced) *ANRIL* transcription in different cancer cells [@B15]. Unlike enforced *ANRIL* overexpression, *P16* reactivation by *P16*-TET restores *ANRIL* expression at the endogenous level (about 10% of *P16* mRNA level). These phenomena imply that it is reactivation of endogenous *P16*, but not *ANRIL* (if any), that mainly contribute to paclitaxel resistance.

Previous studies, including our own, have shown that *P16* methylation is correlated with treatment responses to 5-fluorouracil in locally advanced breast cancer, colorectal cancer, gastric cancer, and other cancers [@B20]-[@B22]. When we re-analyzed our previously published retrospective study on *P16* methylation and 5-fluorouracil among 134 gastric cancer patients [@B22], we found that *P16* methylation was strongly correlated with paclitaxel (and 5-fluorouracil) resistance; 44.9% of the *P16* methylation-negative patients (*N*=49) responded to paclitaxel whereas none of the *P16* methylation-positive patients (*N*=11) responded to paclitaxel (*P*=0.005). However, among the remaining 74 gastric cancer patients who received cisplatin and 5-fluorouracil treatments, no significant differences in responsivity were observed between the *P16* methylation-positive and *P16* methylation-negative patients (4/13 \[30.8%\] vs. 27/61 \[44.3%\], respectively; *P*=0.731). This indicates that *P16* methylation may be a paclitaxel response predictor for cancers in different organs. A large-scale multicenter clinical trial is necessary to determine whether *P16* methylation is beneficial as a predictor of paclitaxel-based treatments for gastric cancer and other cancers.

The *P16* gene is weakly expressed in normal cells and frequently inactivated by DNA methylation in many cancers [@B13],[@B16]-[@B19], [@B37],[@B38]. Because of the limited number of available biopsies, we did not analyze the potential of using P16 immunostaining to predict paclitaxel resistance. P16 functions as a tumor suppressor in normal cell nuclei. However, most P16 proteins are aberrantly located in the cytoplasm of cancer cells. Because of the abnormal compartmentalization of P16 in cancer cells and the *P16* methylation-induced inactivation of both *P16* and *ANRIL*, *P16* methylation and P16 should be considered two different biomarkers.

No significant difference in OS and PFS were seen between patients with or without *P16* methylation. The small case number of our study may account for this phenomenon. In addition, it should be noted that patients received radiotherapy at the same time. The present study only provided an important clue on induction of resistance to paclitaxel by *P16* methylation. To validate the application feasibility of using *P16* methylation as a biomarker to predict paclitaxel resistance, additional clinical trials with specifically defined treatment regimens and larger sample sizes are necessary.

In NSCLC and gastric cancer patients, there were consistent, but not significant, differences in OS durations between *P16* methylation-positive and *P16* methylation-negative patients suggesting that paclitaxel-based treatments result in more short-term benefits than long-term benefits among the *P16* methylation-negative patients. The short-term benefits may be especially useful in decision-making for patients who need to receive neoadjuvant chemotherapy to reduce cancer staging.

In conclusion, the present study demonstrated, for the first time, that *P16* methylation is significantly correlated with the clinical response to paclitaxel-based chemotherapy and may be a potential biomarker to predict paclitaxel resistance in advanced NSCLC. *P16* methylation may directly induce paclitaxel resistance and could be a therapy target for re-sensitizing refractory cancers to paclitaxel-based chemotherapy.
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![**The methylation status of the *P16* CpG islands in NSCLC tissues.** (A) Locations of 70 bp and 150 bp amplicons, primers, and probes used in MethyLight and bisulfite-sequencing (BS), respectively. (B) Bisulfite sequencing results for three representative NSCLC tissue samples (\#1 and \#2, *P16* methylation-positive; \#3, *P16* methylation-negative, by MethyLight). Each line represented a clone; red dot, methylated CpG site; green dash, C-deletion.](jcav10p1726g001){#F1}

![**ROC curve for prediction of paclitaxel responses by different *P16* methylation levels.** The area under the curve is 0.652 (95% CI: 0.49-0.82, P =0.086). Grey dot, cutoff point of the relative copy number of methylated-*P16*, 2.07×10^-4^.](jcav10p1726g002){#F2}

![**Effects of *P16*-specific demethylation by P16-TET on the survival of lung cancer H1299 cells treated with different doses of paclitaxel.** (A) The results of methylation-specific PCR (MSP) to detect demethylated-*P16* alleles in P16-TET stably transfected cells treated with doxycycline for 7 days. (B) The results of quantitative RT-PCR to detect the *P16* mRNA level. (C) The results of MTT assay to detect the viability of P16-TET stably transfected cells. NC, negative control; ^\*^, P\<0.05; ^\*\*^, P\<0.01.](jcav10p1726g003){#F3}

![**Effects of *P16*-specific methylation by P16-Dnmt on the survival of lung cancer HCC827 cells treated with different doses of paclitaxel.** (A) The results of methylation-specific PCR (MSP) to detect methylated-*P16* alleles in P16-Dnmt transiently transfected cells for 48 hours. (B) The results of Western blot to detect P16 protein. (C) The results of MTT assay to detect the viability of HCC827 cells. NC, negative control; ^\*^, P\<0.05; ^\*\*^, P\<0.01.](jcav10p1726g004){#F4}

![**Effects of *P16*-specific methylation on the survival of cancer cell lines treated with different doses of paclitaxel.** (A) DHPLC chromatograms for the detection of fully methylated (P16M), partially methylated (pM), and unmethylated (P16U) *P16* CpG islands (392 bp) in BGC823 cells stably transfected with a *P16*-specific DNA methyltransferase P16-Dnmt or the pTRIPZ control vector. P16-Dnmt expression was induced using doxycycline (dox) for different durations. (B, C) Quantitative RT-PCR and Western blot that detected the P16 expression levels in BGC823 cells. (D) MTT assay to detect the viability of P16-Dnmt stably transfected-BGC823 cells treated with various concentrations of paclitaxel. P16-Dnmt expression in these cells were pre-induced with doxycycline for 14 days. NC, negative control. ^\*^, P\<0.05; ^\*\*^, P\<0.01.](jcav10p1726g005){#F5}

###### 

Clinicopathological characteristics and paclitaxel responses of NSCLC patients with and without *P16* methylation from the clinical trial

                         *N*    *P16* Methylation   *P-* value   
  ---------------------- ------ ------------------- ------------ -------
  **(All)**              45\*   30 (66.7)           15 (33.3)    
  **Gender**                                                     1.000
  Male                   38     25 (65.8)           13 (34.2)    
  Female                 7      5 (71.4)            2 (28.6)     
  **Age**                                                        0.019
  \<60y                  26     21 (80.8)           5 (19.2)     
  ≥60y                   19     9 (47.4)            10 (52.6)    
  **Pathology type**                                             
  Squamous carcinoma     26     14 (53.8)           12 (46.2)    0.031
  Adenocarcinoma         17     14 (82.4)           3 (17.6)     
  Large cell carcinoma   2      2 (100)             0            
  **Clinical stage**                                             0.454
  IIIA                   9      5 (55.6)            4 (44.4)     
  IIIB                   36     25 (69.4)           11 (30.6)    
  **Therapy response**                                           0.004
  Total response         18     16 (53.3)           2 (13.3)     
  Complete response      1      0                   1            
  Partial response       17     16 (94.1)           1 (5.9)      
  No response            27     14 (46.7)           13 (86.7)    
  Stable                 18     9 (50.0)            9 (50.0)     
  Progression            9      5 (55.6)            4 (54.4)     

\* 23 cases from Arm-1 and 22 cases from Arm-2 in the clinical trial

###### 

Analysis of the clinical features and clinical responses using multivariate analysis

                      *OR*    95%CI           Adjusted *P* value
  ------------------- ------- --------------- --------------------
  *P16* methylation   0.085   0.012 - 0.579   0.013
  Sex                 0.267   0.032 - 2.213   0.221
  Age                 1.541   0.344 - 6.910   0.572
  Pathology type      0.470   0.118 - 1.868   0.284
  Clinical stage      1.776   0.298 -10.589   0.528

[^1]: \*Equal contribution

[^2]: Competing Interests: The authors have declared that no competing interest exists.
